AMGN34 Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 5/6 |
Amgen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$49.72 |
52 Week High | US$58.36 |
52 Week Low | US$37.52 |
Beta | 0.59 |
1 Month Change | 0.97% |
3 Month Change | -8.94% |
1 Year Change | 11.58% |
3 Year Change | -0.72% |
5 Year Change | 93.34% |
Change since IPO | 721.65% |
Recent News & Updates
Recent updates
Shareholder Returns
AMGN34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | 0.04% | -3.0% | -1.0% |
1Y | 11.6% | -9.0% | 13.1% |
Return vs Industry: AMGN34 exceeded the BR Biotechs industry which returned -9% over the past year.
Return vs Market: AMGN34 underperformed the BR Market which returned 13.1% over the past year.
Price Volatility
AMGN34 volatility | |
---|---|
AMGN34 Average Weekly Movement | 3.5% |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 4.6% |
10% most volatile stocks in BR Market | 8.7% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: AMGN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: AMGN34's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
AMGN34 fundamental statistics | |
---|---|
Market cap | R$748.13b |
Earnings (TTM) | R$34.46b |
Revenue (TTM) | R$144.60b |
21.9x
P/E Ratio5.2x
P/S RatioIs AMGN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AMGN34 income statement (TTM) | |
---|---|
Revenue | US$28.19b |
Cost of Revenue | US$8.42b |
Gross Profit | US$19.78b |
Other Expenses | US$13.06b |
Earnings | US$6.72b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
Earnings per share (EPS) | 12.52 |
Gross Margin | 70.15% |
Net Profit Margin | 23.83% |
Debt/Equity Ratio | 1,036.8% |
How did AMGN34 perform over the long term?
See historical performance and comparisonDividends
3.3%
Current Dividend Yield68%
Payout RatioDoes AMGN34 pay a reliable dividends?
See AMGN34 dividend history and benchmarksAmgen dividend dates | |
---|---|
Ex Dividend Date | May 16 2024 |
Dividend Pay Date | Jun 13 2024 |
Days until Ex dividend | 22 days |
Days until Dividend pay date | 50 days |
Does AMGN34 pay a reliable dividends?
See AMGN34 dividend history and benchmarks